Vyant Bio, Inc. - FORM 8-K - EX-99.1 - EXHIBIT 99.1 - August 9, 2016

Attached files

file filename
EX-99.2 - EXHIBIT 99.2 - Vyant Bio, Inc.q2slidepresentation.htm
8-K - 8-K - Vyant Bio, Inc.a2016q2pressrelease-form8xk.htm

CANCER GENETICS, INC. REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATES
 
•
Company Reports Quarterly Revenues of $7 million, an increase of 67% over the Second Quarter of 2015
•
The Company’s Organic Growth Rate was 27% over Q1 and 18% over the Second Quarter of 2015, not including revenues from the acquisition closed in Q4 of 2015.
•
Cancer Genetics Continues to Increase Expected Future Revenue from Biopharma Contracts to over $47 Million
•
Cancer Genetics to Host Conference Call Wednesday, August 10, 2016, at 8:30 AM Eastern Time (ET)/5:30 AM Pacific
 
RUTHERFORD, N.J., August 9, 2016 Cancer Genetics, Inc. (Nasdaq: CGIX), an emerging leader in molecular and biomarker-based cancer diagnostics, announced today financial and operating results for the second quarter ended June 30, 2016 and provided other company and business updates.
 
Total revenues were $7.0 million in the second quarter of 2016 and included $4.2 million from Biopharma services and $2.5 million from Clinical services, compared with total revenue of $4.2 million in the second quarter of 2015, an increase of 67 percent.
 
Panna Sharma, Cancer Genetics CEO and President commented, “Our growth and performance during the second quarter was strong and our impact on the oncology community continued to accelerate as a result of our biopharma contracts and our emphasis on providing disease-focused, and clinically actionable genomic as well as immune-marker data and testing capabilities. This along with our innovative portfolio and global infrastructure is truly unique to CGI and a cornerstone of our future growth.”

Other key financial results and highlights for the quarter ended June 30, 2016 include:

▪
Revenues were $7.0 million, a 67% increase over the second quarter of 2015 and a 15% sequential increase over Q1 2016 revenues of $6.1 million;
▪
Revenue from Biopharma Services was $4.2 million, a 58% increase over the second quarter of 2015 and a 26% sequential increase over Q1 2016 revenues of $3.3 million;
▪
Revenue from Clinical Services was $2.5 million, a 103% increase over Q2 2015 and a 4% sequential increase over Q1 2016.
▪
Revenue from Discovery Services was $0.2 million, compared to $0.3 million over the same period of 2015 and essentially flat over Q1 2016.
▪
Gross profit margins improved to 39% a significant improvement from 26% in Q2 2015 and a sequential increase from 32% during Q1 2016.
▪
The Company’s organic growth rate was 18% over Q2 2015 and 27% over Q1 2016
▪
Q2 2016 Clinical Services test volume increased 8% to 7,153 over 6,608 during Q1 2016
▪
Signed contracts for expected future revenue with biotech and pharmaceutical companies increased to over $47 million, a sequential increase of over $6 million from Q1 2016
▪
Total expenses for the quarter were $11.0 million, a reduction of 2.2% from $11.3 million during Q1 2016 largely driven by streamlining workflow across sites and reductions in staff.
▪
Total cash at the end of the quarter was $10.6 million.

For the second quarter ended June 30, 2016, Cancer Genetics reported a net loss of $4.0 million or $0.28 per diluted share, as compared with a net loss of $5.0 million or $0.51 per diluted share during the same period of 2015, and $5.3 million or $0.39 per diluted share for the first quarter of 2016. This is an improvement in net income of 20% year over year and 23% during sequential quarters.


1

Panna Sharma continued, “Our growth areas of immuno-oncology and biopharma partnerships continue to advance our market-share. This is clearly reflected in our Biopharma Services revenue, which comprised 60% of the revenue for the quarter. Additionally, our portfolio of unique and disease-targeted next-generation sequencing (NGS) panels, immune markers, and cell-free DNA capabilities is advancing quickly. Our unmatched and industry-leading portfolio is helping CGI secure collaborations with leading institutions, and revenue-generating relationships with biotech and pharma companies that are working on targeted therapeutics, immuno-oncology targets and companion diagnostics, all of which are leading precursors for future growth and revenue for CGI.”

During the second quarter of 2016, Cancer Genetics also made significant advancements in the development of cell-free or liquid biopsy based genomic tests. The Company expects to launch focused, multi-gene, liquid biopsy tests for lung cancer and renal cancer in the upcoming quarters. Cancer Genetics is also currently involved in a three-way collaboration with Huntsman Cancer Institute at University of Utah and Pfizer in the validation of the Company’s multi-gene signature for determination of renal cancer sub-types that can aid in patient management as well as therapy selection in renal cancer. Additionally, the Company is developing a focused multi-gene assay that can aid in comprehensive diagnosis, monitoring, and therapy selection, including the identification of resistance mutations for non-small cell lung cancer (NSCLC).

Recent Corporate Highlights:

•
Launched a proprietary comprehensive next-generation sequencing (NGS) panel FOCUS::Lymphoma(TM) with CLIA validation to apply in both clinical care and in trials being
•
Biopharmaceutical company, H3 Biomedicine Inc. (H3), a leading company in cancer genomics based drug discovery, selected CGI to provide clinical biomarker services for H3’s lead oncology
•
CGI and Sayre Therapeutics entered into a distribution agreement to commercialize the FDA-cleared Tissue of Origin test throughout India and South Asia
•
The Company announced the offering of multiple FDA-approved PD-L1 tests, including those by DAKO and VENTANA for lung cancer and urothelial cancer, respectively
•
CGI announced results at ASCO with HTG, Keck School of Medicine at USC, and Japan Clinical Cancer Research Organization of using immune-related genes to identify sub-types of patients associated with clinical outcome in metastatic colorectal cancer
•
CGI’s poster highlighting the actionable, clinical value of the FDA-cleared Tissue of Origin test was accepted for presentation at USCAP
•
During Q2 of 2016 CGI brought the total number of immuno-oncology trials that it is providing testing and validation services for to 20, which is up significantly from 12 during the first quarter of 2016
•
Added healthcare industry-veteran John "Jay" Roberts as COO and EVP of Finance

“CGI has a unique platform of capabilities, content and people that are focused on delivering innovation in precision medicine and oncology,” said Jay Roberts, EVP of Finance and COO at Cancer Genetics. “The next phase of our growth will be highly focused on margin expansion and further refining the integration across our sites. This dual focus on innovation and execution will create a durable leader in precision medicine and differentiate us in the marketplace."

CGI will also be providing slides with an overview of the results and discussion points; they will be available at http://ir.cancergenetics.com/presentations.
 
Conference Call & Webcast
Wednesday, August 10, 8:30 AM Eastern Time 
Domestic:                                888-516-2441
International:                           719-457-2089
Conference ID:                        7149112

2

Webcast:                                https://public.viavid.com/index.php?id=120688
  
Replays – Available through August 24, 2016
Domestic:                                877-870-5176
International:                           858-384-5517
Conference ID:                        7149112

ABOUT CANCER GENETICS
Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow CGI at:

Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics

Forward-Looking Statements: 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding future financial and/or operating results and potential for our tests and services, and future revenues or growth in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2015 and the Form 10-Q for the Quarter ended June 30, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Contact:
Panna Sharma
Cancer Genetics, Inc.
201-528-9200
panna.sharma@cgix.com




3

Cancer Genetics, Inc. and Subsidiaries
Consolidated Balance Sheets (Unaudited)
(in thousands, except par value)
 
June 30,
2016
 
December 31,
2015
ASSETS
 
 
 
CURRENT ASSETS
 
 
 
Cash and cash equivalents
$
10,552

 
$
19,459

Accounts receivable, net of allowance for doubtful accounts
11,944

 
6,621

Other current assets
1,970

 
2,118

Total current assets
24,466

 
28,198

FIXED ASSETS, net of accumulated depreciation
5,372

 
6,069

OTHER ASSETS
 
 
 
Restricted cash
300

 
300

Patents and other intangible assets, net of accumulated amortization
1,639

 
1,727

Investment in joint venture
314

 
341

Goodwill
12,029

 
12,029

Other
115

 
220

Total other assets
14,397

 
14,617

Total Assets
$
44,235

 
$
48,884

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
CURRENT LIABILITIES
 
 
 
Accounts payable and accrued expenses
$
7,632

 
$
7,579

Obligations under capital leases, current portion
72

 
122

Deferred revenue
423

 
831

Bank term note, current portion
2,000

 
1,333

Total current liabilities
10,127

 
9,865

Obligations under capital leases
242

 
276

Deferred rent payable and other
306

 
315

Warrant liability
—

 
17

Deferred revenue, long-term
753

 
752

Bank term note
3,648

 
4,642

Total Liabilities
15,076

 
15,867

STOCKHOLDERS’ EQUITY
 
 
 
Preferred stock, authorized 9,764 shares, $0.0001 par value, none issued
—

 
—

Common stock, authorized 100,000 shares, $0.0001 par value, 16,120 and 13,652 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively
2

 
1

Additional paid-in capital
136,590

 
131,167

Accumulated (deficit)
(107,433
)
 
(98,151
)
Total Stockholders’ Equity
29,159

 
33,017

Total Liabilities and Stockholders’ Equity
$
44,235

 
$
48,884




Cancer Genetics, Inc. and Subsidiaries
Consolidated Statements of Operations (Unaudited)
(in thousands, except per share amounts)
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2016
 
2015
 
2016
 
2015
Revenue
$
7,001

 
$
4,185

 
$
13,069

 
$
8,555

Cost of revenues
4,285

 
3,097

 
8,388

 
6,239

Gross profit
2,716

 
1,088

 
4,681

 
2,316

Operating expenses:
 
 
 
 
 
 
 
Research and development
1,680

 
1,256

 
3,212

 
2,533

General and administrative
3,658

 
3,062

 
7,976

 
6,049

Sales and marketing
1,379

 
1,184

 
2,677

 
2,300

Total operating expenses
6,717

 
5,502

 
13,865

 
10,882

Loss from operations
(4,001
)
 
(4,414
)
 
(9,184
)
 
(8,566
)
Other income (expense):
 
 
 
 
 
 
 
Interest expense
(107
)
 
(82
)
 
(233
)
 
(115
)
Interest income
13

 
13

 
17

 
25

Change in fair value of acquisition note payable
67

 
(316
)
 
101

 
(406
)
Change in fair value of warrant liability
—

 
(181
)
 
17

 
(196
)
Total other (expense)
(27
)
 
(566
)
 
(98
)
 
(692
)
Net (loss)
$
(4,028
)
 
$
(4,980
)
 
$
(9,282
)
 
$
(9,258
)
Basic and Diluted Net (Loss) Per Share
$
(0.28
)
 
$
(0.51
)
 
$
(0.66
)
 
$
(0.95
)
Basic and Diluted Weighted-Average Shares Outstanding
14,538

 
9,715

 
14,042

 
9,709




Cancer Genetics, Inc. and Subsidiaries
Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
 
Six Months Ended June 30,
 
2016
 
2015
CASH FLOWS FROM OPERATING ACTIVITIES
 
 
 
Net (loss)
$
(9,282
)
 
$
(9,258
)
Adjustments to reconcile net (loss) to net cash (used in) operating activities:
 
 
 
Depreciation
1,016

 
680

Amortization
174

 
17

Provision for bad debts
—

 
216

Stock-based compensation
1,024

 
1,454

Change in fair value of acquisition note payable
(101
)
 
406

Change in fair value of Gentris contingent consideration
—

 
(162
)
Change in fair value of warrant liability
(17
)
 
196

Amortization of debt issuance costs
6

 
2

Loss in equity method investment
27

 
405

Changes in:
 
 
 
Accounts receivable
(5,323
)
 
(910
)
Other current assets
148

 
(457
)
Other non-current assets
(12
)
 
(73
)
Accounts payable, accrued expenses and deferred revenue
(253
)
 
162

Deferred rent payable and other
(9
)
 
(38
)
Net cash (used in) operating activities
(12,602
)
 
(7,360
)
CASH FLOWS FROM INVESTING ACTIVITIES
 
 
 
Purchase of fixed assets
(319
)
 
(257
)
Decrease in restricted cash
—

 
6,000

Patent costs
(86
)
 
(68
)
Net cash provided by (used in) investing activities
(405
)
 
5,675

CASH FLOWS FROM FINANCING ACTIVITIES
 
 
 
Principal payments on capital lease obligations
(84
)
 
(29
)
Payments for deferred equity offering costs
—

 
(86
)
Proceeds from option exercises
—

 
23

Proceeds from offering of common stock, net of offering costs
4,517

 
—

Principal payments on bank term note
(333
)
 
—

Payment of debt issuance costs
—

 
(33
)
Net cash provided by (used in) financing activities
4,100

 
(125
)
Net (decrease) in cash and cash equivalents
(8,907
)
 
(1,810
)
CASH AND CASH EQUIVALENTS
 
 
 
Beginning
19,459

 
25,554

Ending
$
10,552

 
$
23,744

SUPPLEMENTAL CASH FLOW DISCLOSURE
 
 
 
Cash paid for interest
$
202

 
$
72



Vyant Bio, Inc. Reports